Gedeon Richter PLC Just Missed Revenue By 8.5%: Here's What Analysts Think Will Happen Next
Gedeon Richter PLC (BUSE:RICHTER) shareholders are probably feeling a little disappointed, since its shares fell 5.0% to Ft9,850 in the week after its latest third-quarter results. Revenues came in 8.5% below expectations, at Ft215b. Statutory earnings per share were relatively better off, with a per-share profit of Ft1,307 being roughly in line with analyst estimates. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Gedeon Richter after the latest results.
Taking into account the latest results, the consensus forecast from Gedeon Richter's six analysts is for revenues of Ft1.02t in 2026. This reflects a notable 13% improvement in revenue compared to the last 12 months. Per-share earnings are expected to jump 22% to Ft1,522. Yet prior to the latest earnings, the analysts had been anticipated revenues of Ft1.02t and earnings per share (EPS) of Ft1,533 in 2026. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
View our latest analysis for Gedeon Richter
There were no changes to revenue or earnings estimates or the price target of Ft11,985, suggesting that the company has met expectations in its recent result. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Gedeon Richter analyst has a price target of Ft13,837 per share, while the most pessimistic values it at Ft9,435. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. The period to the end of 2026 brings more of the same, according to the analysts, with revenue forecast to display 10% growth on an annualised basis. That is in line with its 9.9% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 5.1% per year. So it's pretty clear that Gedeon Richter is forecast to grow substantially faster than its industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at Ft11,985, with the latest estimates not enough to have an impact on their price targets.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have forecasts for Gedeon Richter going out to 2027, and you can see them free on our platform here.
It is also worth noting that we have found 1 warning sign for Gedeon Richter that you need to take into consideration.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BUSE:RICHTER
Gedeon Richter
Researches, develops, manufactures, markets, and sells pharmaceutical products.
Undervalued with excellent balance sheet and pays a dividend.
Similar Companies
Market Insights
Community Narratives

